What question did this study set out to answer?

To evaluate the effects of quinapril on exercise capacity in patients with mild chronic heart failure.

March 1, 1993European Heart Journal

A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does quinapril improve exercise capacity in patients with mild chronic heart failure?

Population

32 patients with mild chronic heart failure, mean age 59, 2 females, U.K.-based. Etiology was coronary…

Comparison

Quinapril once daily or twice daily for 8 weeks… vs Placebo for 8 weeks

Design

RCT, three-way cross-over, double-blind

Follow-up

8 weeks per treatment phase

Authors

DNDavid B. NorthridgeEdinburgh Royal Infirmary EREdward RoseRoyal Holloway University of London ERE. D. RAFTERYNorthwick Park Hospital

Discussion

Member takes

Implication

Supports quinapril for exercise capacity gains in mild HF; extends ACEI functional benefits to milder disease.

Key Points

To evaluate the effects of quinapril on exercise capacity in patients with mild chronic heart failure.
Multicenter, double-blind, placebo-controlled trial
32 patients enrolled with mean age 59 years and mild chronic heart failure
Comparison of once daily and twice daily dosing of quinapril over three 8-week treatment phases.
Mean exercise time increased by 65 seconds with once daily quinapril and 53 seconds with twice daily compared to placebo (P <0.01)
No significant difference in exercise capacity between once daily and twice daily dosing
Quinapril did not significantly affect ejection fraction, functional class, or quality of life.

Structured PICO

Does quinapril improve exercise capacity in patients with mild chronic heart failure?

Population

32 patients with mild chronic heart failure (27 NYHA Class II, 5 NYHA Class III), mean age 59, 2 females, U.K.-based. Etiology was coronary artery disease in 29 patients and non-ischaemic in 3. Mean radionuclide ejection fraction 20.4%.

Intervention

Quinapril once daily (o.d.) or twice daily (b.i.d.) (maximal total daily dose 20 mg) for 8 weeks per phase in a three-way cross-over design

Comparator

Placebo for 8 weeks

Outcome

Mean exercise time (treadmill exercise time, modified Bruce protocol) at the end of each 8-week treatment phasesurrogate

Quinapril significantly improves exercise capacity in patients with mild chronic heart failure, with once-daily dosing being as effective as twice-daily dosing.

Cite This Study

Northridge et al. (1993) studied this question.

synapsesocial.com/papers/6a7315f003fe276382acb562 https://doi.org/10.1093/eurheartj/14.3.403

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider